NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-AI-19-033 from the NIH Guide for Grants and Contracts
Notice NOT-HL-19-681 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-NS-19-027 from the NIH Guide for Grants and Contracts. This FOA invites applications that propose to develop, characterize and validate innovative human cellular model systems that recapitulate phenotypic, mechanistic and neuropathological hallmarks of Alzheimers Disease-Related Dementias (ADRDs). Model systems will be expected to capture the complex, multi-faceted proteinopathies and/or vascular pathology observed in ADRDs, with multiple cell types represented in each model. Years 3-5 will focus on the extensive characterization and perturbation of the cellular model systems. The overall goal of this FOA is to establish next generation human cellular model systems for ADRDs to serve as tools to interrogate molecular disease mechanisms and identify potential therapeutic targets.
Funding Opportunity RFA-FD-19-002 from the NIH Guide for Grants and Contracts. Cardiovascular toxicity is a leading cause of drug attrition in drug development. Proarrhythmia, QT prolongation and Torsade de Point (TdP) contribute the most to this attrition and these outcomes drive the efforts spent to eliminate them from the drug discovery pipeline. Currently, these endpoints are evaluated through in vivo preclinical studies followed by a thorough-QT (TQT) study in the clinical phase. T FDA seeks new assays to replace non-clinical cardiotoxicity assessments. Specific interest is in assays based on human cells or materials, collectively covering the spectrum of cardiotoxic drug effects.
Notice NOT-TR-19-014 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-19-173 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages state-of-the-art, systematic research approaches to elucidate the role of immune system plasticity in health and in the pathogenesis of dental, oral, and craniofacial (DOC) diseases. This FOA solicits applications that will seek to determine mechanisms underlying the ability or inability of the immune system to dynamically maintain its functional role against internal and external perturbations. The expectation is that new knowledge derived from this research will facilitate development of novel, personalized immunomodulatory-based therapies that shift the balance between degenerative and regenerative processes toward regeneration disease management in a patient-specific manner across the lifespan.
Funding Opportunity PAR-19-172 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages state-of-the-art, systematic research approaches to elucidate the role of immune system plasticity in health and in the pathogenesis of dental, oral, and craniofacial (DOC) diseases. This FOA solicits applications that will seek to determine mechanisms underlying the ability or inability of the immune system to dynamically maintain its functional role against internal and external perturbations. The expectation is that new knowledge derived from this research will facilitate development of novel, personalized immunomodulatory-based therapies that shift the balance between degenerative and regenerative processes toward regeneration disease management in a patient-specific manner across the lifespan.
Funding Opportunity PA-19-174 from the NIH Guide for Grants and Contracts. This administrative supplement funding opportunity announcement is part of the Beau Biden Cancer MoonshotSM Initiative to accelerate cancer research and was developed in response to a recommendation from the Blue Ribbon Panel of experts charged with advising the National Cancer Advisory Board on the exceptional scientific opportunities that could be accelerated through this initiative. As part of the Cancer Moonshot initiative, the National Cancer Institute (NCI) created the Patient-Derived Xenograft (PDX) Development and Trial Centers Research Network (PDXNet), a collaborative network of centers of excellence focused on using patient-derived xenografts and other patient-derived models to accelerate the development of NCI investigational new drug (IND) agents (i.e., those that the NCI is developing in collaboration with pharmaceutical partners) in NCI-sponsored early phase clinical trials. This FOA supports supplemental funds to current NCI-funded research projects for new interdisciplinary collaborations between non-PDXNet investigators and PDXNet investigators to perform research within the scientific scope(s) of the parent grant and/or cooperative agreement award(s) that will lead to improved pre-clinical evaluations of novel therapeutic concepts using the large-scale PDX model collections of PDXNet, and that could ultimately be tested in NCI-sponsored clinical trials.
Funding Opportunity RFA-MH-20-202 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) invites applications to advance understanding of the role of exposure to violence on engagement and retention in HIV care, HIV medication adherence, and viral suppression, and to develop and test novel interventions to improve HIV outcomes for individuals who have experienced violence.
Funding Opportunity RFA-MH-20-201 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement invites applications to advance understanding of the role of exposure to violence on engagement and retention in HIV care, HIV medication adherence, and viral suppression, and to develop and test novel interventions to improve HIV outcomes for individuals who have experienced violence.
Funding Opportunity RFA-MH-20-200 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) invites applications to advance understanding of the role of exposure to violence on engagement and retention in HIV care, HIV medication adherence, and viral suppression, and to develop and test novel interventions to improve HIV outcomes for individuals who have experienced violence.
Funding Opportunity RFA-DK-18-025 from the NIH Guide for Grants and Contracts. This FOA will support the conduct of advanced clinical trials designed to test the outpatient clinical safety and efficacy of artificial pancreas (AP) device systems in type 1 diabetes with the objective of improving glycemic control, reducing acute complications and improving quality of life. These trials should generate data able to satisfy safety and efficacy requirements by regulatory agencies regarding the clinical testing of AP device systems.
Funding Opportunity RFA-DK-18-026 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for a Data Coordinating Center (DCC) that will support the Advanced Clinical Trials to test Artificial Pancreas device systems. The applicant must have experience serving as the DCCfor studies on complex, clinical conditions including the testing of closed loop platforms for diabetes control.?The DCC will provide overall project coordination, administration, quality control, data management, and biostatistical support.
Funding Opportunity RFA-DK-18-024 from the NIH Guide for Grants and Contracts. The purpose of the KUH/NIDDK Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) is to recruit exceptional graduate students who are recognized by their institutions for their high potential and to incentivize them to pursue a Kidney, Urologic or Hematologic (K, U, or H) postdoctoral position that ultimately positions them to become independent K, U, or H researchers. This two-phase award will facilitate completion of the doctoral dissertation and stablize the transition of highly talented Ph.D candidates from a variety of fields, including, but not limited to, engineering, statistics, data science, imaging, biochemistry and genetics into strong postdoctoral appointments that are focused on K, U or H research. It is anticipated that successful completion of this phased award will make the individual highly competitive for a subsequent NIDDK award (e.g., K99/R00, R01). Opportunities for career development activities relevant to their long-term career goals of becoming independent researchers will be provided. Graduate students who are already involved in K, U, or H research are encouraged to apply for the NIDDK F31 (PA-18-671). This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor
Notice NOT-HS-19-009 from the NIH Guide for Grants and Contracts
Notice NOT-AT-19-021 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-19-171 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated comparative effectiveness research (CER) to the National Institute of Neurological Disorders and Stroke (NINDS). The study must address questions within the mission and research interests of the NINDS and may evaluate preventive strategies, diagnostic approaches, or interventions including drugs, biologics, and devices, or surgical, behavioral, and rehabilitation therapies. Information about the mission and research interests of the NINDS can be found at the NINDS website (https://www.ninds.nih.gov/). Studies proposed should provide a cost-effective means of collecting data with a meaningful bearing on current clinical practice. Awards made under this FOA will initially support a milestone-driven planning phase (UG3) for up to 2 years, with possible transition to a observational study phase of up to five years (UH3). Only UG3 projects that have met the scientific milestones and feasibility requirements may transition to the UH3 phase. The UG3/UH3 application must be submitted as a single application, following the instructions described in this FOA. The UG3 phase for observational studies will permit both scientific and operational planning activities. Scientific planning activities include small-scale data collection to assess the feasibility and/or acceptability of data collection, storage, and planned analyses. Operational planning activities include, at a minimum, development of recruitment and retention strategies, case report forms, data management system and other tools for data and quality management. The UH3 phase of the award will support the conduct of investigator-initiated observational study.
Notice NOT-AA-19-006 from the NIH Guide for Grants and Contracts
Notice NOT-MD-19-019 from the NIH Guide for Grants and Contracts
Notice NOT-OD-19-067 from the NIH Guide for Grants and Contracts